17 results about "Estrous cycle" patented technology

The invention belongs to the field of animal model construction, and particularly relates to application of an NFATC2IP gene knockout mouse model. Experiments prove that after the NFATC2IP gene is knocked out, the mouse has the characteristic changes of ovarian weight reduction, volume reduction, estrus cycle disorder, fertility reduction, AMH reduction, FSH increase and the like. It is indicated that the NFATC2IP gene is a key factor for maintaining ovarian reserve and endocrine balance, and an NFATC2IP gene knockout mouse can be used for revealing the occurrence mechanism of ovarian dysfunction and can also be used for screening of novel ovarian protection drugs, research of a hormone regulation mechanism and discovery and verification of biomarkers.

This invention belongs to the field of biomedicine, and specifically relates to the application of FeTMPyP in the preparation of drugs to alleviate ovarian toxicity. This application addresses the issue that combined exposure to MC-LR and NaNO₂ significantly induces nitrification stress in mouse ovaries, leading to follicular barrier disruption and ovarian reproductive endocrine dysfunction. FeTMPyP was selected as an intervention agent, which effectively alleviated nitrification stress induced by combined exposure to MC-LR and NaNO₂ in mouse ovaries, and improved sex hormone disorders, estrous cycle irregularities, and follicular atresia caused by the combined exposure to these two toxins. Simultaneously, it restored the fertility of mice, indicating that FeTMPyP intervention can alleviate ovarian toxicity induced by combined exposure to MC-LR and NaNO₂ in mice. This invention can be used to prepare drugs to prevent and treat diseases related to ovarian toxicity caused by environmental toxin exposure in mice, providing a new approach for the early identification and targeted intervention of ovarian-related diseases.

The application is application of cooked panax pseudoginseng in preparation of medicine for treating polycystic ovary syndrome, discloses a new use of cooked panax pseudoginseng, i.e. application of cooked panax pseudoginseng in preparation of medicine for treating polycystic ovary syndrome, and proves that cooked panax pseudoginseng can relieve estrous cycle disorder state of mice, improve polycystic-like change of ovary, increase number of corpus luteum, reduce number of atretic follicle and cystic follicle, and restore normal function of ovary; the application provides a new idea for research and development of medicine for treating polycystic ovary syndrome, and cooked panax pseudoginseng can become a potential candidate medicine for treating polycystic ovary syndrome, and has wide application prospect.

This invention discloses a mixed cell preparation and its application in the preparation of drugs for treating premature ovarian failure. The mixed cell preparation comprises granulosa cells and mesenchymal stem cells, mixed in a certain ratio (preferably 1:1). Granulosa cells are obtained by inducing differentiation from mesenchymal stem cells and express granulosa cell-specific markers (FOXL2, FSHR, etc.), participating in follicular structure reconstruction; mesenchymal stem cells can improve the ovarian microenvironment, inhibit inflammation, and resist fibrosis, providing a suitable "soil" for the survival of granulosa cells. In vitro experiments are expected to show that mixed culture can significantly increase estradiol secretion levels and cell survival rate. Animal models of premature ovarian failure are expected to show that mixed cell therapy can significantly restore the estrous cycle, improve hormone levels, increase the number of follicles at all stages, and improve pregnancy rates, with effects significantly superior to single-cell therapy. This invention utilizes the synergistic effect of the two cell types to achieve dual repair of the "seed" and the "soil," providing a novel treatment strategy for premature ovarian failure.

The application belongs to the technical field of biological medicine, and specifically discloses application of 5-methylcytidine in preparation of a medicine for treating polycystic ovary syndrome, which aims to solve the problem that existing treatment methods are difficult to realize synchronous and coordinated improvement on key pathological phenotypes such as estrous cycle disorder, insulin resistance, and hyperandrogenemia, and the 5-methylcytidine involved is a pyrimidine nucleoside natural product, which is high in safety, low in toxic and side effects, and has unique curative effect in treatment of polycystic ovary syndrome.

The present application belongs to the technical field of pharmaceutical preparations, and specifically relates to the new use of Tongren Wuji Baifeng Pills and a pharmaceutical composition in the preparation of a drug for treating premature ovarian failure, a pharmaceutical preparation comprising Tongren Wuji Baifeng Pills, a method for preparing same, and a method for preparing a drug for treating premature ovarian failure. In the present application, a rat model of chemotherapy-induced premature ovarian failure via intraperitoneal injection of cisplatin and a mouse model of immune-mediated premature ovarian failure via multi-point subcutaneous injection of mouse zona pellucida peptide 3 (pZP3) are established. By means of observing the effects of Tongren Wuji Baifeng Pills on the estrous cycles, organ coefficients, serum sex hormone levels, and ovarian histopathological changes in animals in both models, the therapeutic effect of Tongren Wuji Baifeng Pills on premature ovarian failure is verified and clarified. This expands the new clinical use of the drug and provides a new therapeutic drug and means for treating premature ovarian failure, thereby offering technical support for clinical precision medication.

The invention discloses application of umbilical cord mesenchymal stem cells to treatment of premature ovarian insufficiency. The core is that the umbilical cord mesenchymal stem cells (UC-MSC) are pretreated through TAT-IGF-1R-Wnt3a fusion protein so as to enhance the treatment effect. The fusion protein is formed by connecting a TAT cell-penetrating peptide, an IGF-1R active fragment and a Wnt3a active fragment in series through a flexible linker (G4S) 2, and is obtained through recombinant expression and purification of an escherichia coli expression system. UC-MSC pretreated by the fusion protein is transplanted to a premature ovarian insufficiency (POI) mouse model, so that the orbital cycle disorder of a mouse can be remarkably improved, the serum hormone level (reducing FSH and increasing AMH, E2 and P) can be regulated, the ovarian index can be increased, and the treatment effect of the fusion protein is superior to that of unpretreated UC-MSC and a clinically common estradiol valerate treatment scheme; the invention provides a new clinical treatment strategy for premature ovarian insufficiency, and has important application value.

The invention relates to the field of electrochemical biosensing intelligent detection, in particular to a replacement gilt oestrus monitoring intelligent ear tag based on an estradiol sensor. The replacement gilt oestrus monitoring intelligent ear tag comprises an estradiol detection element, a Bluetooth communication module, an electromagnetic interference detection module, a power supply module, a micro-control unit and a cloud data processing module. The local module rapidly screens suspected oestrus data, 90% of invalid data transmission is reduced, and the network bandwidth requirement of a small-scale farm is lowered; the cloud module performs secondary accurate analysis on suspected data in combination with the historical estrus cycle data and the group estrus characteristics of the sows, so that the judgment precision is ensured, and the cost requirement of a small-scale breeding scene is met.

The invention discloses a novel application of a compound MLN4924 (Pevonedat) in preparation of a medicine for improving oocyte quality and treating related diseases, and belongs to the technical field of biological medicines. PCOS animal model experiments prove that the reproductive endocrine indexes of model animals can be remarkably improved by applying the MLN4924, and the reproductive endocrine indexes are specifically represented by restoring the regularity of an estrus cycle and reducing the levels of testosterone and luteinizing hormone in serum; meanwhile, the fertility is improved, and the birth number is increased. In the aspect of oocyte quality, the treatment can increase the number of normal oocytes in an ovary, improve the first polar body discharge rate of in-vitro maturation of the oocytes and improve the blastocyst formation rate after in-vitro fertilization. A further mechanism research shows that the MLN4924 can inhibit the plasmosis of the TRIM21 in the ovarian granular cells and down-regulate the expression level of the protein of the TRIM21. The results show that the MLN4924 provides a new drug choice for developing related diseases for treating polycystic ovarian syndrome (PCOS) and improving oocyte quality.

The invention provides an application of a methoxy isoflavone compound in prevention and treatment of premature ovarian failure. A large number of studies find that the biochanin A and formononetin can effectively improve ovarian reserve function decline or estrus cycle disorder caused by premature senility, adjust the estrogen level, promote follicle development and maturity, increase the ovarian index, increase ovarian reserve and recover the ovarian function. Meanwhile, the biochanin A and the formononetin have the advantages of good stability, high biological activity and low toxicity, can be safely used for preparing medicines for preventing or / and treating ovarian reserve hypofunction and premature senility, and have good patent medicine prospects.

The invention discloses an application of a Polygala fallax Hemsl aqueous extract in preparation of a medicine for treating hypoovarian reserve (DOR), and belongs to the technical field of traditional Chinese medicine Yao medicine. It is found for the first time that the polygala aureocauda aqueous extract can significantly improve the orbital cycle disorder of DOR mice, significantly increase the AMH and E2 levels of the DOR mice, significantly reduce the FSH and LH levels, significantly reduce the atresia follicle rate of the DOR mice and significantly increase the maturation rate of oocytes; therefore, the polygala fallax water extract can be used for treating ovarian reserve function decline and preventing and treating ovarian function impairment caused by chemotherapeutic drugs.

The invention provides a method and system for judging the frozen preparation time based on the mucus viscosity of an estrus cow, and belongs to the technical field of cattle breeding, and the method comprises the following steps: collecting a sample, collecting a cow genital tract mucus sample at regular time after a cow estrus symptom appears, detecting the viscosity parameter of the mucus sample, carrying out threshold model matching on the detected viscosity parameter, and determining the frozen preparation time. And carrying out data association optimization, and carrying out frozen preparation reminding and pushing reminding. The method comprises the following steps: collecting genital tract mucus samples of an oestrus cow at different stages, acquiring a dynamic viscosity value and an elastic modulus value of mucus by utilizing a viscosity detection device, and automatically judging that the cow is in an optimal freezing preparation window stage in combination with a preset mucus viscosity characteristic threshold model; meanwhile, the system can associate cow estrus cycle data with historical frozen preparation records, further optimizes the judgment result, and finally pushes accurate frozen preparation time suggestions to the user. The determination accuracy of the frozen preparation time can be improved to 92% or above, the conception rate and the reproduction efficiency of cows are remarkably improved, and the labor cost and the misjudgment risk are reduced.

The invention relates to a group of complex microbial inoculants for improving lipid metabolism and application of the complex microbial inoculants in treatment of polycystic ovarian syndrome. The complex microbial inoculants for improving lipid metabolism comprise an inactivated bifidobacterium bifidum strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.1. 2212 and an inactivated Lactobacillus crispatus strain with the preservation number of CGMCC No.1. 2743. The complex microbial inoculants for improving lipid metabolism are compounded and combined for use, the two components can cooperate with each other and promote each other, and play roles in recovering the estrus cycle of mice, reducing the number of cystic follicles, reducing androgens, reducing LH hormones and improving the polycystic ovarian syndrome.

The application relates to the field of biotechnology, and particularly relates to a method for obtaining a biological marker of a buffalo estrus period and application of the biological marker to identifying the buffalo estrus period, S1, collecting milk samples of a female buffalo, and observing follicle development of the female buffalo by using B ultrasonic waves; S2, after the milk samples are extracted, analysis is conducted by using a quadrupole-electric field orbitrap high-resolution mass spectrometry system and an ultrafast high-performance liquid chromatography system; S3, after original data are converted into an mzXML format, extraction data are obtained by using XCMS software processing, the extraction data are processed and analyzed, and significant difference metabolites of cow milk in an estrus period are screened out; S4, expression amounts of the significant difference metabolites of the cow milk in the estrus period and a non-estrus period are detected, the expression amount changes are compared with B ultrasonic wave results, and a biological marker of the buffalo estrus period is obtained. Compared with the prior art, pyridoxamine and homovanillic acid are obtained as the biological marker of the estrus period of the female buffalo, and are used for identifying whether the female buffalo is in the estrus period.

The application belongs to the technical field of biological medicine, and discloses application of beta-elemene acid or a derivative or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating polycystic ovary syndrome (PCOS). The beta-elemene acid is screened from a medicinal and edible homology library, and experiments prove that the beta-elemene acid can significantly improve the ovary morphology and mature follicle quantity of PCOS, normalize the estrous cycle, significantly improve the serum hormone level, and also significantly improve the glucose tolerance, insulin tolerance and body weight of PCOS. The beta-elemene acid of the application is a compound based on medicinal and edible homology, which can be used as a medicine and also as a natural ingredient of food, has low toxicity, is safe in long-term use, has low cost of safety evaluation of a relatively new synthetic compound, and can be applied to development and preparation of a medicine for preventing and / or treating PCOS or a lead compound thereof.

The invention discloses a traditional Chinese medicine Yao medicine for improving an ovarian reserve function and application thereof, and belongs to the technical field of traditional Chinese medicine Yao medicines. It is found for the first time that the Ziyuan aqueous extract can significantly improve the orbital cycle disorder of DOR mice, significantly increase the AMH and E2 levels of the DOR mice, significantly reduce the FSH and LH levels, significantly reduce the atresia follicle rate of the DOR mice and significantly increase the maturation rate of oocytes; therefore, the Ziyuan water extract can be used for treating ovarian reserve function decline and preventing and treating ovarian function impairment caused by chemotherapeutic drugs.

The invention relates to an application of dihydroartemisinin in preparation of medicines for preventing, delaying and / or treating ovarian senescence and related diseases thereof. It is found for the first time that dihydroartemisinin can effectively prevent, delay and / or treat ovarian senescence, including ovarian fibrosis and age-related fertility decline caused by ovarian fibrosis. Dihydroartemisinin significantly improves the ovary structure and function through the multi-target synergistic effect of regulating reproductive endocrine, inhibiting senescence-related phenotypes, resisting ovarian fibrosis and the like, specifically, the oestrus cycle is recovered, the ovary weight is increased, and the ovulation number and the litter size are increased. Moreover, the invention also proves that dihydroartemisinin has the potential of preventing fertility decline in a middle-aged model, is good in safety, does not cause injury to main visceral organs and reproductive organs, has normal liver and kidney function indexes, and provides a new strategy for clinical intervention of ovarian senescence.